Tuberculosis News and Research

Latest Tuberculosis News and Research

Bristol-Myers Squibb and Mylan expand access to HIV drug Reyataz in sub-Saharan Africa and India

Bristol-Myers Squibb Company today announced a new agreement to expand access to Reyataz (atazanavir sulfate). The immunity-from-suit agreement signed with Matrix Laboratories Limited, a Mylan Company, enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India.

29 Jun 2011

Researchers identify new component of plague causing bacterium that can be used as a vaccine

Researchers from the Smiley lab at the Trudeau Institute have now identified a single component of the plague causing bacterium that can be used as a vaccine. This single "subunit" could potentially be used to create a safer form of a T cell-stimulating plague vaccine. The new data is featured in the July issue of The Journal of Immunology.

27 Jun 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Promising results of the Phase I clinical trial of the generic drug BCG to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego.

27 Jun 2011

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.

24 Jun 2011

Woods Institute at Stanford University awards seven new Environmental Venture Project grants

The Woods Institute for the Environment at Stanford University has awarded seven new Environmental Venture Projects (EVP) grants for interdisciplinary research aimed at finding practical solutions promoting global sustainability.

24 Jun 2011

Evolutionary-management strategies to limit spread of drug-resistant diseases

In the war between drugs and drug-resistant diseases, is the current strategy for medicating patients giving many drug-resistant diseases a big competitive advantage?, asks a research paper that will be published in the Proceedings of the National Academy of Sciences.

24 Jun 2011

Global Fund signs onto International Aid Transparency Initiative

The Global Fund to Fight AIDS, Tuberculosis and Malaria announced Thursday that "it has become a signatory of the International Aid Transparency Initiative, which "means that grant information currently on the Global Fund website will be aligned to an internationally agreed set of standards" and "financial and grant activity data and documentation will be accessible to a broader audience and will be comparable to information provided by other donors," according to a Global Fund press release.

24 Jun 2011

Eradicating malaria is a 'realistic possibility'

Eliminating malaria in endemic countries is a "realistic possibility if those countries keep expanding malaria prevention and treatment at the pace set in recent years," Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, writes on the Bill & Melinda Gates Foundation's blog.

23 Jun 2011

Rats help tackle humanitarian issues

John Campbell, a senior fellow for Africa Policy Studies at the Council on Foreign Relations, writes about "HeroRATs" in this CFR blog post.

22 Jun 2011

DIA recognizes CAPRISA team for outstanding achievement in HIV prevention

Today the CAPRISA 004 study leadership team is being awarded the inaugural Drug Information Association (DIA) President's Award for Outstanding Achievement in World Health.

21 Jun 2011

IPS examines access to treatment for drug-resistant TB

"Access to treatment for drug-resistant tuberculosis remains compromised, especially in developing countries, because too few pharmaceutical companies manufacture quality-assured drugs," Inter Press Service reports in an article examining how a lack of competition and a working mechanism to keep prices low "has led to skyrocketing prices."

21 Jun 2011

Pakistan facing challenging TB epidemic

Pakistan has one of the highest rates of tuberculosis (TB) in the world, with nearly 70,000 TB-related deaths each year, Al-Jazeera English reports.

21 Jun 2011

Researchers use DNA library to create potential cancer vaccine

University of Leeds researchers, funded by Cancer Research UK, have used a library of DNA to create a vaccine that could be used to treat cancer, according to a study published in Nature Medicine.

20 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

Local misconceptions of children's immune systems hindering HIV treatment in Malawi, study says

Some caregivers in rural Malawi have expressed a reluctance to begin antiretroviral therapy for children living with HIV because of a belief that their "bodies were too weak for pills and their blood was 'still raw,' but that as it 'ripened' with time, HIV-related opportunistic infections would leave them," according to a study presented this week at the 1st International HIV Social Science and Humanities Conference in Durban, South Africa, PlusNews reports.

15 Jun 2011

New opportunities to save another 6.4 million lives

Vaccinating children around the world against infectious diseases has saved the lives of millions over the past several decades. Now new opportunities exist to overcome remaining challenges-and save another 6.4 million lives over the current decade, according articles in the June 2011 edition of Health Affairs. The issue was produced under the journal's grant from the Bill & Melinda Gates Foundation.

10 Jun 2011

Free access to enteric pathogen's genetic regulation data

Just a few genes make enterohaemorrhagic E. coli (EHEC) extremely dangerous to humans. If it were not for these genes, EHEC would hardly differ from harmless enteric bacteria. Bioinformatics scientists from the Saarbr-cken Cluster of Excellence want to exploit this similarity to find starting points for effective drugs against the EHEC pathogen.

10 Jun 2011

Researchers and advocates form new vaccine foundation

Researchers and "advocates for all vaccine research today launched yet another effort to increase funding and coordination," ScienceInsider reports. The Foundation for Vaccine Research "has recruited a board stacked with several prominent HIV/AIDS researchers," the article notes.

10 Jun 2011

The ‘decade of vaccines’ has the potential to save lives, many challenges ahead

Vaccinating children around the world against infectious diseases has saved the lives of millions over the past several decades. Now new opportunities exist to overcome remaining challenges—and save another 6.4 million lives over the current decade, according articles in the June 2011 edition of Health Affairs. The issue was produced under the journal’s grant from the Bill & Melinda Gates Foundation.

9 Jun 2011

Scientists, advocacy experts form new international Foundation for Vaccine Research

Fourteen leading scientists and advocacy experts in vaccines and infectious diseases have announced the formation of a new international Foundation to advance and accelerate vaccine research and development against infectious diseases.

9 Jun 2011